Pharsight

Kyprolis patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US7232818 ONYX THERAP Compounds for enzyme inhibition
Apr, 2025

(1 year, 6 months from now)

US8207297 ONYX THERAP Compounds for enzyme inhibition
Apr, 2025

(1 year, 6 months from now)

US8207125 ONYX THERAP Compounds for enzyme inhibition
Apr, 2025

(1 year, 6 months from now)

US7417042 ONYX THERAP Compounds for enzyme inhibition
Jul, 2026

(2 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8207127 ONYX THERAP Compounds for enzyme inhibition
Apr, 2025

(1 year, 6 months from now)

US8129346 ONYX THERAP Compounds for enzyme inhibition
Apr, 2025

(1 year, 6 months from now)

US7491704 ONYX THERAP Compounds for enzyme inhibition
Apr, 2025

(1 year, 6 months from now)

US8207126 ONYX THERAP Compounds for enzyme inhibition
Apr, 2025

(1 year, 6 months from now)

US7737112 ONYX THERAP Composition for enzyme inhibition
Dec, 2027

(4 years from now)

USRE47954 ONYX THERAP Combination therapy with peptide epoxyketones
Oct, 2029

(6 years from now)

US9511109 ONYX THERAP Combination therapy with peptide epoxyketones
Oct, 2029

(6 years from now)

US9493582 ONYX THERAP Alkylated cyclodextrin compositions and processes for preparing and using the same
Feb, 2033

(9 years from now)

Kyprolis is owned by Onyx Therap.

Kyprolis contains Carfilzomib.

Kyprolis has a total of 12 drug patents out of which 0 drug patents have expired.

Kyprolis was authorised for market use on 20 July, 2012.

Kyprolis is available in powder;intravenous dosage forms.

Kyprolis can be used as use in combination with lenalidomide plus dexamethasone for the treatment of patients with relapsed or refractory multiple myeloma who have received one to three lines of therapy, kyprolis is indicated in combination with lenalidomide plus dexamethasone for the treatment of patients with relapsed or refractory multiple myeloma who have received one to three lines of therapy, kyprolis is indicated as a single agent for the treatment of patients with relapsed or refractory multiple myeloma who have received one or more lines of therapy; kyprolis is indicated in combination with dexamethasone or with lenalidomide plus dexamethasone for the treatment of patients with relapsed or refractory multiple myeloma who have received one to three lines of therapy; treatment of patients with multiple myeloma who have received at least two prior therapies including bortezomib and an immunomodulatory agent and have demonstrated disease progression on or within 60 days of completion of the last therapy; kyprolis is indicated in combination with daratumumab plus dexamethasone for the treatment of patients with relapsed or refractory multiple myeloma who have received one to three lines of therapy, treatment of patients with multiple myeloma who have received at least two prior therapies including bortezomib and an immunomodulatory agent and have demonstrated disease progression on or within 60 days of completion of the last therapy; kyprolis is indicated as a single agent for the treatment of patients with relapsed or refractory multiple myeloma who have received one or more lines of therapy; kyprolis is indicated in combination with dexamethasone or with lenalidomide plus dexamethasone for the treatment of patients with relapsed or refractory multiple myeloma who have received one to three lines of therapy; kyprolis is indicated in combination with daratumumab plus dexamethasone for the treatment of patients with relapsed or refractory multiple myeloma who have received one to three lines of therapy, treatment of patients with multiple myeloma who have received at least two prior therapies including bortezomib and an immunomodulatory agent and have demonstrated disease progression on or within 60 days of completion of the last therapy; kyprolis is indicated in combination with dexamethasone or with lenalidomide plus dexamethasone for the treatment of patients with relapsed or refractory multiple myeloma who have received one to three lines of therapy; kyprolis is indicated as a single agent for the treatment of patients with relapsed or refractory multiple myeloma who have received one or more lines of therapy; kyprolis is indicated in combination with daratumumab plus dexamethasone for the treatment of patients with relapsed or refractory multiple myeloma who have received one to three lines of therapy.

The generics of Kyprolis are possible to be released after 27 February, 2033.

Drug Exclusivity Drug Exclusivity Expiration
New Indication (I) Aug 20, 2023

Drugs and Companies using CARFILZOMIB ingredient

Market Authorisation Date: 20 July, 2012

Treatment: Treatment of patients with multiple myeloma who have received at least two prior therapies including bortezomib and an immunomodulatory agent and have demonstrated disease progression on or within 60 ...

Dosage: POWDER;INTRAVENOUS

How can I launch a generic of KYPROLIS before it's drug patent expiration?
More Information on Dosage

KYPROLIS family patents

Family Patents

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic